EagleBio/iLite IL-12检测就绪细胞/BM4012

价格
¥24800.00
货号:BM4012
浏览量:127
品牌:EagleBio
服务
全国联保
正品保证
正规发票
签订合同
商品描述

iLite IL-12 Assay Ready Cells

iLite IL-12 Assay Ready Cells Developed and Manufactured by Svar Life Science

The Eagle Biosciences iLite® IL-12 Assay Ready Cells are intended for:

  • Testing IL-12 or p40 inhibitor activity
  • Testing NAb response against IL-12

For Research Use Only


Key benefits of iLite® Assays


  • Highly specific reporter gene cell lines
  • Very sensitive cell line responses (>10 fold inductions)
  • Assay Ready Cells – ready-to-use from the freezer, without culturing of cells
  • Assays within a workday (typically 4-7 hour assays)
  • Normalization gene, which eliminates unwanted matrix effects

Assay Background

Interleukin 12 (IL-12) is a 70 kDa cytokine produced principally by macrophages, neutrophils and dendritic cells in response to stimulation by antigen. IL-12 is a T cell-stimulating factor, playing a critical role in the regulation of T-helper 1 cell responses. IL-12 is composed of two subunits, p35 and p40, covalently linked by a single disulfide bond. The p40 subunit, which binds to the receptor chain IL-12Rβ1, is shared with another heterodimeric cytokine, IL-23. However, the two cytokines expert distinct non-redundant biological functions (1). Therapeutic agents targeting both IL-12 and IL-23 cytokines are currently used to treat psoriasis and psoriatic arthritis, and related agents are in clinical testing for a variety of inflammatory disorders (2).

iLite® IL-12 ARCs are a genetically engineered reporter gene cell line (DT-40, ATCC#CRL-2111) responsive to Interleukin-12 by specific and proportional expression of Firefly Luciferase. Normalization of cell counts and serum matrix effects is obtained by a second reporter gene, a Renilla Luciferase reporter gene construct, under the control of a constitutive promotor.


Products Related to IL-12 Assay Ready Cells

Human IL-12 p40 ELISA Assay Kit
Human IL-12 p70 ELISA Assay Kit
IL-2 Assay Ready Cells

EagleBio的iLite®分析就绪细胞iLite®  技术基于报告基因检测格式,经过修改和适用于整个药物开发周期中的应用以及生物药物的监测。这些细胞系可以开发用于任何生物制药靶标,并且可以使用相同的细胞系轻松设置药物效力(即药物活性)的测定方法。检验就绪的细胞经过基因工程处理,可与报告基因检验技术一起使用,以检测药物效力和NAb。